RECRUITING

Molecular Signatures of Cutaneous Dupilumab Response

Talk to us

Conditions

Atopic Dermatitis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Official Title

Molecular Signatures of Cutaneous Dupilumab Response

Quick Facts

Study Start:2023-02-01
Study Completion:2026-02-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05858619

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. 18 years of age or older
  2. 2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7
  1. 1. Known pregnancy
  2. 2. Known immunodeficiencies
  3. 3. Known parasitic infection -

Contacts and Locations

Study Contact

Jeffrey Cheng, MD, PhD
CONTACT
415 575 0524
rashes@ucsf.edu

Principal Investigator

Jeffrey Cheng, MD, PhD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Raymond Cho, MD, PhD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Jeffrey Cheng, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco
  • Raymond Cho, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-02-01
Study Completion Date2026-02-01

Study Record Updates

Study Start Date2023-02-01
Study Completion Date2026-02-01

Terms related to this study

Additional Relevant MeSH Terms

  • Atopic Dermatitis